Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $53.71 USD
Change Today -0.79 / -1.45%
Volume 391.9K
NLNK On Other Exchanges
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

newlink genetics corp (NLNK) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/9/15 - $58.73
52 Week Low
10/13/14 - $17.32
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEWLINK GENETICS CORP (NLNK)

newlink genetics corp (NLNK) Details

NewLink Genetics Corporation, a biopharmaceutical company, focuses on discovering, developing, and commercializing immunotherapeutic products to enhance treatment options for patients with cancer. Its portfolio includes biologic product candidates based on its HyperAcute immunotherapy technology, which is designed to stimulate the human immune system; and small-molecule product candidates that are focused on breaking the immune system's tolerance to cancer by inhibiting the indoleamine-(2,3)-dioxygenase pathway and the tryptophan-(2.3)-dioxygenase pathway. The company’s lead product candidate, HyperAcute Pancreas immunotherapy, is being studied in Phase III clinical trials in surgically-resected pancreatic cancer patients, as well as in patients with advanced pancreatic cancer. It is also developing HyperAcute Lung immunotherapy for treating advanced non-small cell lung cancer; and HyperAcute Melanoma immunotherapy for treating advanced melanoma, as well as HyperAcute immunotherapies for renal, prostate, and breast cancers. In addition, the company is developing IDO pathway inhibitors comprising indoximod and NLG919 for metastatic breast cancer and metastatic prostate cancer; NLG2101 for patients with metastatic breast cancer; NLG2102 for treating refractory malignant brain tumors; NLG2103 for patients with advanced melanoma; and NLG2014 for patients with metastatic pancreatic cancer. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

130 Employees
Last Reported Date: 03/16/15
Founded in 1999

newlink genetics corp (NLNK) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $573.2K
President, Chief Operations Officer and Chief...
Total Annual Compensation: $453.6K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $90.0K
Clinical & Regulatory Compliance Officer and ...
Total Annual Compensation: $312.2K
Vice President of Business Development
Total Annual Compensation: $262.5K
Compensation as of Fiscal Year 2014.

newlink genetics corp (NLNK) Key Developments

Merck and Newlink Genetics Corporation Announces Initiation of Third, Late-Stage, Clinical Trial of their Ebola Vaccine Candidate rVSV-ZEBOV-GP

Merck and NewLink Genetics Corporation confirmed that the third, late-stage, clinical trial of their Ebola vaccine candidate rVSV-ZEBOV-GP (V920) has been initiated in Sierra Leone. The vaccine candidate was originally developed by the Public Health Agency of Canada’s National Microbiology Laboratory and licensed to NewLink Genetics in 2010. On Nov. 24, 2014, Merck and NewLink Genetics announced an exclusive licensing and collaboration agreement for the investigational Ebola vaccine. The Phase II/III safety and effectiveness study, called STRIVE (Sierra Leone Trial to Introduce a Vaccine against Ebola) taking place in Sierra Leone will involve 6,000 health and other frontline workers and is being led by the Sierra Leone College of Medicine and Allied Health Sciences, Sierra Leone Ministry of Health and Sanitation, and the U.S. Centers for Disease Control and Prevention (CDC). The Merck and NewLink rVSV-ZEBOV-GP vaccine candidate is now included in three large-scale clinical trials currently underway in West Africa. In addition to the trial in Sierra Leone, these trials are: The Partnership for Research on Ebola Vaccines in Liberia (PREVAIL): Led by a Liberia-U.S. clinical research partnership and sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), PREVAIL was designed to enroll approximately 27,000 healthy men and women aged 18 years and older. This randomized, controlled Phase II/III study to evaluate safety and efficacy, involves rVSV-ZEBOV-GP and another experimental Ebola vaccine. Based on declining Ebola virus incidence in Liberia, the trial leaders have determined that it is scientifically appropriate to expand the trial to additional sites in other West African countries. Discussions are underway to explore that possibility, but the trial has not yet expanded outside of Liberia. Phase III study in Guinea: The World Health Organization (WHO), the Health Ministry of Guinea, Médecins sans Frontières (MSF), Epicentre and The Norwegian Institute of Public Health have initiated a safety and effectiveness study investigating Merck’s and NewLink’s rVSV-ZEBOV-GP, the vaccine candidate that was selected by the WHO and study partners to be assessed first in this study.

NewLink Genetics Corporation Presents at 2015 Jefferies Immuno-Oncology Summit, Apr-15-2015 12:20 PM

NewLink Genetics Corporation Presents at 2015 Jefferies Immuno-Oncology Summit, Apr-15-2015 12:20 PM. Venue: Boston, Massachusetts, United States.

Merck & Co and NewLink Genetics Announce Positive Clinical Trial Results for Vaccine Candidate VSV-ZEBOV in the Prevention of Ebola Virus Infection

Merck & Co and NewLink Genetics have published positive clinical trial results examining their vaccine candidate VSV-ZEBOV in the prevention of Ebola virus infection. In the US component of the clinical trials, 52 healthy volunteers were vaccinated with either a higher- or lower-dose version of the vaccine, while others were given a placebo. Of the 40 patients who received the vaccine, all exhibited Ebola antibody production within 28 days, with higher antibody production noted in the higher-dose arm of the trial. In another set of trials, 158 volunteers in Gabon, Germany, Kenya, and Switzerland were inoculated, with one of five doses of the vaccine or a placebo. Once again, all patients who received the vaccine exhibited antibody production. No serious adverse events were reported, although, as previously reported, the trial of the vaccine in Switzerland was temporally halted following complaints of joint pain from clinical trial participants. The results are positive for the development of a vaccine to combat Ebola. However, the development of the vaccine remains in its early stages and the effectiveness of the vaccine will only become apparent through larger Phase III clinical trials. Unusually for drug development, the development of Ebola therapies and vaccines has been fast-tracked, with the Phase III trial of the vaccine having started in March, before the publication of Phase I results. Companies conducting clinical trials in the country may face challenges in maintaining cold chain storage, obtaining informed consent, and data collection, all necessary functions for clinical trials. For those developing therapies, as opposed to vaccines, falling cases of Ebola may make it challenging to recruit patients for Phase III clinical trials.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NLNK:US $53.71 USD -0.79

NLNK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NLNK.
View Industry Companies

Industry Analysis


Industry Average

Valuation NLNK Industry Range
Price/Earnings 16.2x
Price/Sales 8.7x
Price/Book 7.4x
Price/Cash Flow 14.9x
TEV/Sales 7.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEWLINK GENETICS CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at